Magnetar Financial LLC Lowers Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Magnetar Financial LLC lowered its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 20.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,712,258 shares of the biotechnology company’s stock after selling 947,120 shares during the quarter. Magnetar Financial LLC owned about 1.60% of ADMA Biologics worth $41,503,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Quest Partners LLC acquired a new position in ADMA Biologics during the second quarter worth approximately $29,000. EntryPoint Capital LLC acquired a new position in shares of ADMA Biologics during the first quarter worth about $31,000. CWM LLC raised its stake in shares of ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 4,367 shares during the period. Acadian Asset Management LLC acquired a new position in shares of ADMA Biologics during the second quarter worth $93,000. Finally, Viewpoint Capital Management LLC boosted its stake in shares of ADMA Biologics by 18.6% in the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 2,416 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $19.98 on Monday. ADMA Biologics, Inc. has a 12-month low of $3.06 and a 12-month high of $20.16. The firm has a market capitalization of $4.63 billion, a price-to-earnings ratio of -999.00 and a beta of 0.61. The business has a 50 day simple moving average of $15.77 and a 200 day simple moving average of $11.00. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same quarter in the prior year, the firm posted ($0.02) EPS. ADMA Biologics’s revenue was up 78.4% compared to the same quarter last year. On average, equities research analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 466,900 shares of company stock valued at $8,224,121. Corporate insiders own 3.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a research note on Friday. HC Wainwright upped their price target on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Mizuho raised their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $15.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.